| Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. WJ Ho, Q Zhu, J Durham, A Popovic, S Xavier, J Leatherman, A Mohan, ... Nature cancer 2 (9), 891-903, 2021 | 175 | 2021 |
| Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity WJ Ho, Q Zhu, J Durham, A Popovic, S Xavier, J Leatherman, A Mohan, ... Nature Cancer 2 (9), 891-903, 2021 | 75 | 2021 |
| Systemic inhibition of PTPN22 augments anticancer immunity WJ Ho, S Croessmann, J Lin, ZH Phyo, S Charmsaz, L Danilova, ... The Journal of Clinical Investigation 131 (17), 2021 | 40 | 2021 |
| Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways WJ Ho, R Erbe, L Danilova, Z Phyo, E Bigelow, G Stein-O’Brien, ... Genome biology 22 (1), 154, 2021 | 40 | 2021 |
| Profiling of syngeneic mouse HCC tumor models as a framework to understand anti–PD‐1 sensitive tumor microenvironments DJ Zabransky, L Danilova, JM Leatherman, TY Lopez‐Vidal, J Sanchez, ... Hepatology 77 (5), 1566-1579, 2023 | 38 | 2023 |
| Feasibility and efficacy of neoadjuvant cabozantinib and nivolumab in patients with borderline resectable or locally advanced hepatocellular carcinoma (HCC). M Yarchoan, Q Zhu, JN Durham, N Gross, S Charmsaz, JM Leatherman, ... Journal of Clinical Oncology 39 (3_suppl), 335-335, 2021 | 27 | 2021 |
| Multipanel mass cytometry reveals anti–PD-1 therapy–mediated B and T cell compartment remodeling in tumor-draining lymph nodes WJ Ho, M Yarchoan, S Charmsaz, RM Munday, L Danilova, MB Sztein, ... JCI insight 5 (2), 2020 | 23 | 2020 |
| A global live cell barcoding approach for multiplexed mass cytometry profiling of mouse tumors S Charmsaz, N Gross, E Jaffee, WJ Ho JCI insight 6 (7), 2021 | 13 | 2021 |
| Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials DN Sidiropoulos, GL Stein-O’Brien, L Danilova, NE Gross, S Charmsaz, ... JCI insight 7 (19), 2022 | 12 | 2022 |
| Multimodal immune phenotyping reveals microbial-T cell interactions that shape pancreatic cancer Y Li, RB Chang, ML Stone, D Delman, K Markowitz, Y Xue, H Coho, ... Cell Reports Medicine 5 (2), 2024 | 7 | 2024 |
| Fibroblasts in the aged pancreas drive pancreatic cancer progression DJ Zabransky, Y Chhabra, ME Fane, E Kartalia, JM Leatherman, L Hüser, ... Cancer Research 84 (8), 1221-1236, 2024 | 6 | 2024 |
| Entinostat in combination with nivolumab in metastatic pancreatic ductal adenocarcinoma: a phase 2 clinical trial M Baretti, L Danilova, JN Durham, CB Betts, L Cope, DN Sidiropoulos, ... Nature communications 15 (1), 9801, 2024 | 3 | 2024 |
| Immune-related events in individuals with solid tumors on immunotherapy associate with Th17 and Th2 signatures CJ Kao, S Charmsaz, SL Alden, M Brancati, HL Li, A Balaji, K Munjal, ... The Journal of Clinical Investigation 134 (20), 2024 | 3 | 2024 |
| CyTOF protocol for immune monitoring of solid tumors from mouse models SM Shin, A Hernandez, E Coyne, K Munjal, NE Gross, S Charmsaz, ... STAR protocols 4 (1), 101949, 2023 | 3 | 2023 |
| Abstract B003: Validating PTPN22 as a cancer-agnostic immunotherapeutic target JS Babu, S Charmsaz, NE Gross, AG Hernandez, CD Cannon, X Yuan, ... Cancer Immunology Research 12 (10_Supplement), B003-B003, 2024 | 1 | 2024 |
| Phosphodiesterase-5 inhibition collaborates with vaccine-based immunotherapy to reprogram myeloid cells in pancreatic ductal adenocarcinoma NE Gross, Z Zhang, JT Mitchell, S Charmsaz, AG Hernandez, EM Coyne, ... JCI insight 9 (18), e179292, 2024 | 1 | 2024 |
| Abstract CT016: Immunomodulation of the tumor microenvironment of pancreatic ductal adenocarcinoma with histone deacetylase inhibition: Results of a phase 2 clinical trial of … M Baretti, L Danilova, JN Durham, CB Betts, L Cope, DN Sidiropoulos, ... Cancer Research 84 (7_Supplement), CT016-CT016, 2024 | 1 | 2024 |
| Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma DJ Zabransky, E Kartalia, JW Lee, JM Leatherman, S Charmsaz, ... Hepatology, 10.1097, 2024 | 1 | 2024 |
| Imaging mass cytometry reveals key spatial features among immune cells in hepatocellular carcinomas treated with neoadjuvant cabozantinib and nivolumab S Zhang, Q Zhu, N Gross, S Charmsaz, A Deshpande, S Xavier, A Mohan, ... Cancer Research 81 (13_Supplement), 1682-1682, 2021 | 1 | 2021 |
| PTPN22 is a systemic target for augmenting antitumor immunity WJ Ho, J Lin, L Danilova, Z Phyo, S Charmsaz, A Mohan, T Armstrong, ... Cancer Research 80 (16_Supplement), 3398-3398, 2020 | 1 | 2020 |
Nicole GrossThe Johns Hopkins University School of Medicine在 jhmi.edu 的电子邮件经过验证
Nicole GrossThe Johns Hopkins University School of Medicine在 jhmi.edu 的电子邮件经过验证